NCT05656131View on ClinicalTrials.gov

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

March 30, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Interventions
DRUG

Fluzoparib

Arms A will be treated with fluzoparib alone

DRUG

Fluzoparib+Camrelizumab

Arms B will be treated with fluzoparib in combination with camrelizumab

Trial Locations (1)

Unknown

RECRUITING

Sun-yat sen university cancer center, Guangzhou

All Listed Sponsors
lead

wang shusen

OTHER